Osteoactivin is a type I transmembrane protein upregulated by unloading stresses, including denervation, prolonged bed rest, and space flight, but the regulatory mechanisms of its expression and activation under these conditions remain undefined. Here we report that osteoactivin protein exists in two forms: an intact transmembrane form and a secreted form. The secreted form, the extracellular fragment of osteoactivin, was produced by ectodomain shedding and was released into a culture medium. Amino acid sequence analysis of the carboxy-terminal fragment of osteoactivin (OA-CTF) revealed that cleavage of osteoactivin by proteases occurred both at the cell surface and within the cell membrane. Localization analysis demonstrated translocalization of OA-CTF to the nucleus and the endoplasmic reticulum. Moreover, RNA binding proteins, which regulate pre-mRNA splicing, were identified as OA-CTF binding proteins. These results suggest that OA-CTF formed by ectodomain shedding is involved in the regulation of pre-mRNA splicing.
Osteoactivin, a type I transmembrane protein, is a rat homolog of the Gpnmb (glycoprotein nonmetastatic melanoma protein B) family, originally reported to be highly expressed in human melanoma cells. 1) Previous studies reported that osteoactivin transcripts increase in various diseases associated with fibrosis, such as osteopetrosis and liver cirrhosis. 2, 3) Furthermore, microarray analysis of the gastrocnemius muscle of space flight rats indicated upregulation of the osteoactivin gene under microgravity conditions. 4) The expression of osteoactivin mRNA is also upregulated in gastrocnemius muscles treated by denervation and tail-suspension, similarly to the findings for space flight, 5) but the regulatory mechanisms of its expression and the physiological function of osteoactivin undefined.
Several type I transmembrane proteins, including Notch and HB-EGF, are activated by proteolysis on the cell surface (ectodomain shedding). 6, 7) Previous studies have established the involvement of metalloprotease disintegrins, ADAM, and certain matrix metalloproteinases (MMPs) in this ectodomain shedding. 8, 9) In addition, ectodomain proteolysis is followed by proteolytic processing by the -secretase complex within the transmembrane domain. 10) Furthermore, recent reports indicate that HB-EGF and Notch are cleaved by both ADAMs and -secretase [11] [12] [13] and that the released carboxy-terminal fragment of Notch and HB-EGF translocates to the nucleus and acts as a transcriptional regulator. 6, 14) In the present study, we found that ectodomain proteolysis resulted in the formation of intracellular and extracellular osteoactivin fragments. Hence, one can assume that the behavior of the intracellular osteoactivin fragment is similar in Notch and HB-EGF. We were able to identify the site of osteoactivin cleavage using proteases and RNA binding proteins, acting as candidate interacting proteins of the carboxy-terminal osteoactivin fragment (OA-CTF).
Pre-mRNA splicing by RNA binding protein is functionally coupled to transcription, and regulation of it is essential to the survival of cells in biotransformation. 15) Changes in splice site choice are regulated by proteins that bind to the pre-mRNA and affect spliceosome assembly. One of the well-studied protein families of splicing regulatory factors is the SR protein, which plays important roles in both constitutive and alternative splicing and act at various stages of spliceosome assembly. 16) Splicing factor arginine/serine-rich 9 (SFRS9/SRp30c) belongs to the SR family.
17) The heterogeneous nuclear ribonucleoproteins (hnRNPs) are another large group of proteins that bind to nascent premRNAs. HnRNP A1, an hnRNP protein, regulates the transcription, processing of primary transcripts, nuclear export, subcellular localization, and stability of mature mRNA. 18) HnRNPs are also involved in alternative splicing regulation in that they antagonize the activity of the SR family of proteins. 19) The present study sought to clarify the physiological role of osteoactivin. The results indicate that osteoactivin was activated by shedding and that the released OA-CTF translocated to the nucleus. In addition, OA-CTF interacted with RNA binding proteins. These results are the first to suggest that osteoactivin is a key regulatory protein in pre-mRNA splicing under unloading conditions.
Materials and Methods
Cell lines and culture conditions. HEK293T cells (human embryonic kidney cell line) were purchased from GenHunter (Nashville, TN). COS-7 cells were the kind gift of Dr. Taketani (University of Tokushima). All the cells were maintained and proliferated at 37 C under 5% CO 2 /95% air in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 100 U/ mL of penicillin, and 100 mg/mL of streptomycin.
SDS-PAGE and immunoblotting. SDS-8, 12%-polyacrylamide gel electrophoresis (PAGE) was performed under reducing conditions by the method of Laemmli. 20) For immunoblotting analysis, proteins in the gels were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 3.5% skim milk in 50 mM Tris-HCl, 150 mM NaCl, pH 7.4 (TBS), and then incubated with primary antibodies for 1 h at 25 C. The primary antibodies used were as follows: anti-osteoactivin (R&D Systems, Minneapolis, MN), anti-V5 (Invitrogen, Carlsbad, CA), and anti-FLAG (Sigma, St. Louis, MO) antibody. The bound antibodies were detected using an appropriate secondary antibody and the enhanced chemiluminescence system (ECL) (GE Healthcare UK, Buckinghamshire, UK). Protein concentrations were determined by the BCA method, with bovine serum albumin as standard.
Detection of osteoactivin cleavage sites. HEK293T cells were transfected with V5-tagged osteoactivin and cultured for 24 h. The cell lysates were incubated overnight with anti-V5 antibody-conjugated agarose (Sigma, St. Louis, MO) at 4 C. After washing, OA-CTF was eluted with 0.1 M glycine-HCl (pH 3.5). The elutant was analyzed by amino acid sequencing with an Applied Biosystems 492 Gas-Phase Sequencer/140C System, following the instructions provided by the manufacturer.
Immunocytochemical analysis. Immunocytochemical analysis was done to localize osteoactivin. Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS). After washing 3 times with PBS, the cells were incubated with monoclonal anti-mouse V5 antibody (Invitrogen) or anti-PDI (protein disulfide isomerase; a endoplasmic reticulum marker) antibody (Axxora, Farmingdale, NY) at 4 C for 18 h. After washing with PBS, the cells were incubated with secondary Alexa 488-conjugated anti-mouse IgG (Molecular Probes, Eugene, OR) and Alexa 568-conjugated anti-rabbit IgG (Molecular Probes) for 1 h at room temperature in the dark. At the same time, they were incubated with Hoechst-33342 (Dojindo, Kumamoto, Japan) or LysoTracker (Invitrogen, Carlsbad, CA).
Cellular fractionation. COS-7 cells were transfected with and without plasmids containing carboxyl-terminal-V5-tagged OA-FL, and then cultured for 24 h. They were pre-treated with 50 mg/mL of cycloheximide for 2 h. Then they were fractionated with a ProteoExtract Ò Subcellular Proteome Extraction Kit, Mini (Calbiochem, San Diego, CA). The extracted proteins (15 mg/lane) were subjected to Western blotting. Protein concentrations were determined by the BCA method with bovine serum albumin as standard.
Nuclear extract preparation. COS-7 cells were transfected with Mock or plasmids containing carboxyl-terminal-FLAG-tagged OA-CTF and cultured for 24 h. Then they were overlaid with a minimal volume of warm 0.05% trypsin-EDTA, harvested by centrifugation at 1;000 Â g, and washed in cold PBS. All subsequent processes were performed at 0-4 C. The cell pellet was resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, and protease inhibitors). The cell suspension was kept on ice for 10 min, and then 10% NP-40 (final concentration 0.5%) was added. The suspension was vortexed 10 s to obtain cell nuclei. After centrifugation at 4;000 Â g for 10 min, the nuclear pellets were resuspended in hypertonic buffer (20 mM HEPES-NaOH pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 25% glycerol, 0.1 mM EDTA, and protease inhibitors). Then the nuclei were vortexed for 30 min and centrifuged at 4;000 Â g for 20 min. Finally, the nuclear proteins in the supernatant were retrieved, and the protein concentrations were determined by the BCA method with bovine serum albumin as standard.
Detection of proteins co-immunoprepicipated with OA-CTF. The nuclear proteins obtained from FLAG-tagged OA-CTF-expressing cells were incubated overnight with anti-FLAG antibody-conjugated agarose (Sigma) at 4 C. After washing, OA-CTF was eluted with 0.1 M glycine-HCl (pH 3.5). The elutant was applied to SDS-PAGE, and the target proteins were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS).
Liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The purified FLAG-tagged OA-CTF and OA-CTF-binding proteins were subjected to SDS-PAGE and were detected by staining with silver nitrate by standard procedures. The peptide mixtures were applied to high-performance liquid chromatography (HPLC) on an Atlantis dC18 column (0:075 Â 150 mm) (Waters, Milford, MA). Analytical separation was done using a gradient elution with 5% acetonitrile as mobile phase A and 95% acetonitrile as mobile phase B, both containing 0.1% formic acid. After an isocratic step of 5% B for 3 min, this was gradually increased to 95% B in 44 min, and held for 5 min. The flow rate was maintained at 0.2 mL min À1 . HPLC was connected to an ion-trap mass spectrometer equipped with an orthogonal electrospray ionization interface (Nanoflow-LC ESI, positive). MS control, data acquisition, and data analysis were done using Q-Tof Ultima API (Waters/Micromass UK, Manchester, UK). The MS conditions were capillary voltage 2.8 kV, and collision energy 13-65 eV. Mass spectra were registered in m=z 300-1950, and mass/mass in m=z 50-1950. The data obtained were analyzed by Mascot Search (MS/MS Ion Search).
Expression and purification of recombinant proteins. For the expression of GST-fusion proteins, the SFRS9 gene was amplified using a specific primer pair, 5 0 -TTGAATTCATGTCGGGCTG-3 0 and 5 0 -CGCTCGAGTCAGTAGGGC-3 0 , and a specific primer pair for hnRNP A1 gene, 5 0 -CCGAATTCATGTCTAAGTCAGAG-3 0 and 5 0 -CGCTCGAGTTAAAATCTTCTGC-3 0 . The PCR products were cloned into the XhoI/EcoRI site of the pGEX 6p-1 vector (GE Healthcare UK). GST fusion proteins were expressed in BL21 cells. After induction with 0.5 mM isopropyl-D-thiogalactopyranoside (IPTG) (12 h, 20 C), the cells were sonicated in PBS containing 1% Triton X-100. Purification of the fusion proteins was performed as described using GSTrap FF (GE Healthcare UK). For the expression of His-and Myc-tagged OA-CTF, the OA-CTF gene was amplified using a specific primer pair, 5 0 -CGCTCGAGATACAAAAAACACAAGGCGGTA-3 0 and 5 0 -AAGAATTCGAGTGTCCTTGGCTTGGCTTGTCCTG-3 0 . The PCR product was cloned into the XhoI/EcoRI site of the pBAD vector (Invitrogen). OA-CTF-myc/His were expressed in Top10 cells (0.002% arabinose, 4 h, 30 C). For purification of the expressed protein, Ni-NTA affinity chromatography (Invitrogen) was done following the instructions supplied by the manufacturer.
GST pull-down assay. For GST pull-down assay, 2-5 mg the GSTfusion protein was mixed with 2-5 mg the OA-CTF-myc/His coupled and rotated overnight at 4 C in PBS containing 0.005% Triton X-100. Then 20 mL, glutathione-sepharose 4B (GE Healthcare UK) was added, and this was incubated for 3 h at 4 C. Bound proteins were washed 3 times with cold PBS and eluted with SDS sample buffer. The resulting samples were applied to 15% SDS-PAGE and analyzed by immunoblotting.
Results
Osteoactivin is released by proteolytic cleavage at both the cell surface and the intramembrane A number of type I transmembrane proteins have an active form after ectodomain shedding on the cell surface. 6, 14) First, we examined to determine whether the osteoactivin protein, a type I transmembrane protein, can also shed due to proteases. As shown in Fig. 1A and B, intact transmembrane forms of osteoactivin with molecular masses of 97 and 116 kDa were detected in the cell lysates, and secreted forms with molecular masses of 90 and 100 kDa were detected in the conditioned media. In addition, a small fragment of osteoactivin (OA-CTF) of a molecular mass approximately 20 kDa was detected in the cell lysates but not in the conditioned media. These results suggest that osteoactivin-full length (OA-FL) was shed after expression the at membrane surface of the cells, and produced two fragments (extracellular and intracellular fragments) by proteolytic cleavage. Next, we explored the shedding point of osteoactivin by amino acid sequence analysis of OA-CTF. As shown in Fig. 1C , three shedding points were identified. In particular, based on the yield of phenylthiohydantoin (PTH)-amino acid, two major points were identified as candidate cleavage sites. One was the position between Arg 499 and Ale 500 , which is located in the extracellular region of osteoactivin, and the other was between Leu 505 and Ile 506 , localized in the plasma membrane. This suggests that osteoactivin is activated by ectodomain shedding at both the cell surface and within the cell membrane.
OA-CTF translocated to the nucleus and the endoplasmic reticulum
Next we analyzed the intracellular localization of the osteoactivin fragment. For this purpose, carboxyl-terminal-V5-tagged OA-FL expression plasmid was transfected. To maintain the production of OA-CTF and reduce the synthesis of OA-FL, the cells were pretreated with cycloheximide (CHX), an inhibitor of protein biosynthesis. Then the ratio of abundance OA-FL/OA-CTF was analyzed by Western blotting using anti-V5 antibody. As shown in Fig. 2A , the amount of OA-CTF was greater than that of OA-FL at 2 to 6 h after incubation with CHX. Hence, the cells were stained by immunofluorescence methods using anti-V5 antibody after treatment with CHX for 2 h (Fig. 2B) . OA-FL was mapped in the plasma membrane, cytoplasm and nucleolus. In contrast, OA-CTF was localized mainly in the nucleoplasm, and possibly the endoplasmic reticulum. OA-CTF was co-stained with PDI (protein disulfide isomerase; a endoplasmic reticulum marker) but not with LysoTracker (a lysosome marker). Further, we confirmed the localization of OA-CTF on fractionation of the cells (Fig. 2C) . OA-CTF was observed in the extracts of the cytosolic protein fraction (F1), organelle and membrane fraction (F2), and nucleic fraction (F3). This suggests that OA-CTF released by shedding translocates to the nucleoplasm.
OA-CTF interacted with RNA binding proteins in the nucleus
Since translocation of OA-CTF was observed after proteolytic processing, next we tried to identify the OA-CTF interacting proteins. As shown in Fig. 3 , two proteins were co-precipitated with FLAG-tagged OA-CTF from the nuclear proteins of OA-CTF-expressing cells. Analysis of these proteins by LC-MS/MS identified candidate proteins that interact with OA-CTF (Table 1) . Among the proteins detected, we investigated the interaction between hnRNPA1 and OA-CTF and between SFRS9 and OA-CTF. To determine whether these proteins can bind to OA-CTF, a GST-pull-down assay was performed. As shown in Fig. 4 , SFRS9 and hnRNPA1 interacted with OA-CTF. This suggests that the released intracellular domain of osteoactivin interacted with SFRS9 and/or hnRNPA1 and is involved in pre-mRNA splicing.
Discussion
Osteoactivin transcripts increase in various diseases associated with fibrosis, including osteopetrosis and liver cirrhosis, but the role of osteoactivin is poorly understood. In the present study, first we determined the cleavage of osteoactivin at both the cell surface and in the membrane (Fig. 1C) . Proteolytic ectodomain release, a process known as shedding, has emerged as a key mechanism in the regulation of the functions of various cell surface proteins. Shedding of integral membrane proteins is limited to type I transmembrane proteins, in which the cleavage site is generally located close to the membrane surface. 13) Although several proteases may be involved in this proteolysis, MMP or a disintegrin and metalloproteases (ADAM) mainly mediate the process. 8, 9) In addition, -secretase complex, an intramembrane protease, also mediates the shedding process. 13) Recent studies have reported that ADAM10 is a candidate sheddase that releases osteoactivin ectodomain from the cell surface, 21) but as shown in Myc and His-tagged OA-CTF were purified from Escherichia coli and then incubated overnight with GST, GST-SFRS9, or GSThnRNP A1 at 4 C. GST pull-down assay was performed as described in ''Materials and Methods.'' GST fusion SFRS9 and hnRNP A1 were identified by immunoblotting with anti-GST antibody (asterisks). Co-immunoprepicipated Myc/His-OA-CTF was detected by immunoblotting with anti-Myc antibody. WB, Western blotting. MMSTD, molecular mass standards. Fig. 1C , the cleavage site of osteoactivin is located at both the cell surface and within the membrane. Therefore, not only ADAM10 but also -secretase may be involved in the ectodomain shedding of osteoactivin.
In the present study, we also found that OA-CTF appeared to internalize and translocate to the nucleus or the endoplasmic reticulum (Fig. 2) . Notch and HB-EGF, also a type I trans-membrane protein, has been reported to act as a regulator of transcription. 6, 14) These types of proteins release the active intracellular domain, which is translocated into the nucleus and modulates gene expression by induction of a complex of transcription initiation proteins. These reports suggest that OA-CTF as well as Notch and HB-EGF also interact with certain proteins and have certain roles in the nucleus. Unlike Notch and HB-EGF, osteoactivin interacted with RNA binding proteins, which are involved in pre-mRNA splicing. Orvain et al. 22) have reported that transcription factor c-Myb influences alternative pre-mRNA splicing via interactions with splicing factor U2AF and hnRNP A1. The present study suggests that OA-CTF affect alternative pre-mRNA splicing by interacting with premRNA splicing factor SFRS9 and hnRNPA1 based on the finding of interactions between OA-CTF and both SFRS9 and hnRNP A1 (Fig. 4) . In contrast to the interaction between OA-CTF and SFRS9, the interaction between OA-CTF and hnRNP A1 appeared to be weak. HnRNP A1 can increase binding affinity to partner proteins in the presence of mediating proteins. 23) Therefore, some mediating protein might exist for hnRNP A1 to bind more firmly to OA-CTF.
Previous studies have documented the functions of the SR protein and hnRNP A1 in muscles. Chalfant et al. 24, 25) reported that phosphorylated SR protein acts through the phosphatidylinositol 3-kinase pathway via insulin-regulated alternative splicing of PKCII mRNA in the skeletal muscle. In another study, phosphorylation of hnRNP A1 led to translocation of mRNA-bound hnRNP A1 from the nucleus to the cytoplasmic stress granules (SGs) during stress.
26) The SGs have cytoplasmic domains that harbor translationally arrested mRNAs that accumulate in cells exposed to a broad range of stresses, including oxidative, genotoxic, hyperosmotic, and heat shock. These reports suggest that phosphorylation of RNA binding proteins is required for them to function. Hence, the function of OA-CTF appears to be regulated by phosphorylated SR proteins or hnRNPs.
In summary, here we report three major findings concerning osteoactivin expression and function. First, osteoactivin upregulated by unloading stresses was cleaved by proteases both at the cell surface and within the cell membrane. Secondly, proteolytic release of OA-CTF resulted in translocation to the nucleus. Thirdly, OA-CTF interacted with SR proteins or hnRNPs that belong to pre-mRNA splicing factors. Although further studies are required, OA-CTF appears to regulate premRNA splicing under microgravity conditions.
